Company News
Sun Pharma Presents UNLOXCYT Long-Term aCSCC Data at ESMO
Sun Pharma will present long-term efficacy and safety data for UNLOXCYT in advanced cutaneous squamous cell carcinoma at ESMO 2026.
The study shows 34% complete response rate in locally advanced patie
